Regulatory Filings • Mar 16, 2018
Regulatory Filings
Open in ViewerOpens in native device viewer
Renewed NICE recommendation for adopting Medistim technology in the NHS
(Oslo, March 16th, 2018) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that NICE recommends the adoption of Medistim's MiraQ system in the NHS for routine intraoperative graft flow assessment in patients having CABG surgery.
Approximately 17,000 isolated coronary artery bypass graft (CABG) operations are performed in the UK each year. In addition, a substantial proportion of patients having other cardiac surgery have concomitant CABG. The National Institute for Health and Care Excellence (NICE) provides national guidelines and advice to improve health and social care in the UK. In their recent update of the Medical technologies guidance, MTG8, they state that based on this large number of patients, a reduction in graft occlusion rates during CABG surgery potentially offers significant cost savings to the National Health System (NHS).
In their report, NICE says that "The case for adopting the MiraQ system in the NHS for assessing graft flow during CABG is supported by clinical evidence. The evidence suggests that intraoperative transit time flow measurement (TTFM) is effective in detecting imperfections that may be corrected by graft revision. This may reduce the incidence of graft occlusion and may reduce perioperative morbidity and mortality. The MiraQ system is associated with an estimated cost saving of £141 per patient compared with clinical assessment alone, when it is used routinely for assessing CABG surgery in every patient."
Kari E. Krogstad, President and CEO at Medistim states, «Medistim is very much encouraged by this renewed support from the MTG8 committee at NICE and further that the estimated cost saving per surgery has increased from £115 to £141 from the previous 2011 guidance. The UK is a very important market for us, with significant growth opportunity and we have established a subsidiary with direct sales representation in this country. Hence, this recommendation fuels our ongoing efforts to increase the adoption of both our TTFM and high frequency ultrasound imaging in this key market. In addition, a NICE guidance are highly recognized in the global market as well. "
About Medistim:
Medistim was established in 1984, and has a track record of profitable growth over the past >10 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the US, Germany, Denmark, UK, Spain and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa and South America. For more information, visit the Medistim home page:
www.Medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.